NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.87 -0.13 (-0.16%) GOLD FUTURES
2,316.90 +5.90 (+0.26%) DOW
38,192.70 +289.41 (+0.76%) Bitcoin GBP
47,396.84 +1,213.15 (+2.63%)
BIO Jun 2024 470.000 call
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.7000 |
| Ask | 2.5500 |
| Strike | 470.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksEarnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).
ZacksAnalysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
